Tenderwize
Retour à la recherche

Open house discount agreements for the active ingredient Umeclidinium bromide, ATC R03BB07

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Apr 30, 2027 · 192 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Umeclidiniumbromid, ATC R03BB07

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

25 / 100

Facteurs de risque

No minimum volume or revenue guarantee; the contract is non-exclusive and can be terminated or replaced by exclusive co...

The buyer reserves the right to replace open house agreements with exclusive discount contracts, leading to automatic t...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Apr 30, 2027

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Entering into non-exclusive discount agreements for the active ingredient Umeclidinium bromide (ATC R03BB07) with pharmaceutical companies.
  • Agreements cover the supply of authorized and marketable drugs in Germany.
Afficher le résumé complet

Non-exclusive open house discount agreements for the active ingredient Umeclidinium bromide (ATC R03BB07) in Germany, offered by AOK Rheinland-Pfalz/Saarland. The model allows any pharmaceutical company to join at any time during the 24-month period from 01.07.2025 to 30.06.2027, with uniform terms and no competitive selection. The agreements may be replaced by exclusive discount contracts during the term.

Risques

No minimum volume or revenue guarantee; the contract is non-exclusive and can be terminated or replaced by exclusive co...

The buyer reserves the right to replace open house agreements with exclusive discount contracts, leading to automatic t...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Drugs must be authorized and marketable in Germany (proof via Lauer-Taxe or AMIce database).

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submission of signed contract documents: either handwritten in duplicate or electronically with a qualified electronic signature (QES).

Critères d'attribution

Lot 1

No award criteria; open house model with automatic acceptance.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open house discount agreements for the active ingredient Umeclidinium bromide, ATC R03BB07

Non-exclusive discount agreements for Umeclidinium bromide drugs, open to all pharmaceutical companies. Contracts have a maximum duration of 24 months, starting at the beginning of any month. The first possible start date is 01.07.2025. The agreements can be terminated with 6 weeks' notice and replaced by exclusive discount agreements.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; open house model with automatic acceptance.

Date limite

Deadline Apr 30, 2027

Détails de la procédure

Date de publication
18 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
319668-2025

Documents (1)

Appels d'offres similaires